Vesugen
KED · Vascular Bioregulator Peptide
Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.
Overview
Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.
Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Protects blood vessels from age-related deterioration through gene expression regulation.
Limits development of atherosclerotic plaques in blood vessels.
Decreases endothelial dysfunction that contributes to cardiovascular disease.
Regulates sirtuin 1 levels, mimicking some benefits of calorie restriction.
Enhances mesenchymal stem cell proliferation and reduces senescence.
Reverses senescence-associated secretory phenotype in aging cells.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tripeptide bioregulator
- Chain length
- 3 residues
- Molecular weight
- 390 Da
- Typical dose
- 10-20 mg per day (oral capsules) or 10 mg (injectable)
- Frequency
- Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
- Cycle length
- 10-20 day cycle
- Storage
- Oral capsules: room temperature; Lyophilized powder/reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Tripeptide bioregulator
- Molecular weight
- 390 Da
- Chain length
- 3 residues
KEDDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Research protocol | IM or SubQ | 10 mg | Daily for 10 days |
Interactions
Complementary cardiovascular bioregulators - Vesugen for vessels, Cardiogen for heart tissue.
Often combined in comprehensive anti-aging Khavinson protocols.
Different organ targets; can be used in comprehensive bioregulator protocols.
Part of Khavinson bioregulator family; targets different tissue.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual cardiovascular symptoms
- Active cardiovascular emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQ
Does Vesugen activate SIRT1 like calorie restriction and can it be used with fasting?
Yes, Vesugen regulates SIRT1 (sirtuin 1) protein levels, mimicking some benefits of calorie restriction without requiring dietary restriction. Combining Vesugen with intermittent fasting or calorie restriction could theoretically provide synergistic SIRT1 activation and enhanced anti-aging effects, though this combination hasn't been formally studied.
How does Vesugen prevent atherosclerosis and is it effective for existing plaques?
Vesugen limits atherosclerosis development by reducing endothelial dysfunction and activating SIRT1 anti-aging pathways in vascular tissue. It's preventive rather than plaque-reversal focused. Early atherosclerosis prevention works better than treating advanced disease, so Vesugen is most valuable as a cardiovascular health maintenance peptide.
Can Vesugen be combined with other Khavinson bioregulators like Epitalon?
Yes, Vesugen and Epitalon are synergistic in comprehensive anti-aging protocols. Vesugen targets vascular aging while Epitalon addresses pineal/endocrine aging - using them together provides multi-system rejuvenation. They're often combined in Khavinson anti-aging programs with Thymalin or Vilon for enhanced effects.
Does Vesugen reduce senescent cell burden or just prevent new senescence?
Vesugen reduces senescence markers and reverses the Senescence-Associated Secretory Phenotype (SASP) in aging cells through stem cell activation and epigenetic regulation. This suggests it may reduce existing senescent cells, though the primary mechanism is prevention and restoration rather than elimination of aged cells.